Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

On June 21, 2024 (the "Effective Date"), Personalis, Inc. (the "Company") and Foresight Diagnostics, Inc. ("Foresight") entered into a Settlement and License Agreement (the "S&L Agreement") pursuant to which the Company and Foresight agreed to settle certain previously disclosed litigation pending in U.S. federal district court (the "Litigation") and inter-partes review proceedings (the "IPRs") pending before the U.S. Patent Trial and Appeal Board (the "PTAB") in each case related to certain patents of the Company.

Pursuant to the S&L Agreement, Foresight and the Company agreed to stipulate to dismiss pending claims of infringement and related defenses and counterclaims in the Litigation and request authorization from the PTAB to request termination of the IPRs and the Company granted Foresight a non-exclusive, worldwide license under certain patents of the Company to develop, manufacture, commercialize and otherwise exploit products and services that use whole genome sequencing and a variable content minimal/molecular residual disease panel that utilizes phased variants in consideration for which Foresight agrees to pay the Company a low-single digit tiered royalty on net sales of products and services covered by patents licensed by Company, subject to customary reductions. The license is perpetual and irrevocable, except in certain limited circumstances, which apply on a patent-by-patent basis. Upon the occurrence of certain specified change of control events involving specified parties with respect to Foresight, the highest percentage of the royalty tiers is subject to a very low single digit increase and Foresight will pay to Company a one-time fee in the low single-digit millions. Foresight and the Company also agreed, pursuant to the S&L Agreement, for each to release the other party from certain claims related to the Litigation, the IPRs, the licensed patents and the licensed products and services, and related facts and circumstances. Each of Foresight and the Company further covenanted not to sue the other party with respect to certain products and services covered by certain patents owned or controlled by each party or certain of its affiliates. The term of the S&L Agreement runs through expiration of the patents licensed by Company to Foresight.

The Company may terminate the license and the parties' covenant not to sue with respect to any licensed patent if Foresight challenges the licensed patent.

The foregoing summary of the S&L Agreement is qualified in its entirety by reference to the full text of the S&L Agreement, a copy of which is attached to this report as Exhibit 10.1, which is incorporated herein by reference.